Literature DB >> 25064471

Dosimetric predictors of esophageal toxicity after stereotactic body radiotherapy for central lung tumors.

Abraham J Wu1, Eric Williams2, Ankit Modh3, Amanda Foster3, Ellen Yorke2, Andreas Rimner3, Andrew Jackson2.   

Abstract

BACKGROUND AND
PURPOSE: Stereotactic body radiotherapy (SBRT) to central lung tumors can cause esophageal toxicity, but little is known about the incidence or risk factors. We reviewed central lung SBRT patients to identify dosimetric factors predictive of esophageal toxicity.
MATERIALS AND METHODS: We assessed esophageal toxicity in 125 SBRT patients. Using biological equivalent doses with α/β=10 Gy (BED₁₀), dose-volume histogram variables for the esophagus (Dv and Vd) were assessed for correlation with grade ⩾2 acute toxicity.
RESULTS: Incidence of grade ⩾2 acute toxicity was 12% (n=15). Highly significant logistic models were generated for D₅cc and Dmax (p<0.001). To keep the complication rate <20%, the model requires that D₅cc⩽26.3 BED₁₀. At 2 years, the probability of complication with BED₁₀D₅cc>14.4 Gy was 24%, compared to 1.6% if ⩽14.4 Gy.
CONCLUSIONS: This novel analysis provides guidelines to predict acute esophageal toxicity in lung SBRT. Dose to the hottest 5cc and Dmax of the esophagus were the best predictors of toxicity. Converting the BED₁₀ limits to physical doses, D₅cc to the esophagus should be kept less than 16.8, 18.1 and 19.0 Gy for 3, 4, and 5 fractions, respectively, to keep the acute toxicity rate <20%.
Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Central; Esophagitis; Esophagus; Hypofractionated; Lung; SBRT

Mesh:

Year:  2014        PMID: 25064471      PMCID: PMC4254177          DOI: 10.1016/j.radonc.2014.07.001

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  22 in total

1.  Esophageal tolerance to high-dose stereotactic ablative radiotherapy.

Authors:  J A Abelson; J D Murphy; B W Loo; D T Chang; M E Daly; E A Wiegner; S Hancock; S D Chang; Q-T Le; S G Soltys; I C Gibbs
Journal:  Dis Esophagus       Date:  2011-12-13       Impact factor: 3.429

2.  Stereotactic body radiation therapy for inoperable early stage lung cancer.

Authors:  Robert Timmerman; Rebecca Paulus; James Galvin; Jeffrey Michalski; William Straube; Jeffrey Bradley; Achilles Fakiris; Andrea Bezjak; Gregory Videtic; David Johnstone; Jack Fowler; Elizabeth Gore; Hak Choy
Journal:  JAMA       Date:  2010-03-17       Impact factor: 56.272

3.  Stereotactic body radiation therapy: the report of AAPM Task Group 101.

Authors:  Stanley H Benedict; Kamil M Yenice; David Followill; James M Galvin; William Hinson; Brian Kavanagh; Paul Keall; Michael Lovelock; Sanford Meeks; Lech Papiez; Thomas Purdie; Ramaswamy Sadagopan; Michael C Schell; Bill Salter; David J Schlesinger; Almon S Shiu; Timothy Solberg; Danny Y Song; Volker Stieber; Robert Timmerman; Wolfgang A Tomé; Dirk Verellen; Lu Wang; Fang-Fang Yin
Journal:  Med Phys       Date:  2010-08       Impact factor: 4.071

4.  The lessons of QUANTEC: recommendations for reporting and gathering data on dose-volume dependencies of treatment outcome.

Authors:  Andrew Jackson; Lawrence B Marks; Søren M Bentzen; Avraham Eisbruch; Ellen D Yorke; Randal K Ten Haken; Louis S Constine; Joseph O Deasy
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-03-01       Impact factor: 7.038

5.  Improving normal tissue complication probability models: the need to adopt a "data-pooling" culture.

Authors:  Joseph O Deasy; Søren M Bentzen; Andrew Jackson; Randall K Ten Haken; Ellen D Yorke; Louis S Constine; Ashish Sharma; Lawrence B Marks
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-03-01       Impact factor: 7.038

6.  Outcome of four-dimensional stereotactic radiotherapy for centrally located lung tumors.

Authors:  Joost J Nuyttens; Noelle C van der Voort van Zyp; John Praag; Shafak Aluwini; Rob J van Klaveren; Cornelis Verhoef; Peter M Pattynama; Mischa S Hoogeman
Journal:  Radiother Oncol       Date:  2012-01-20       Impact factor: 6.280

7.  Outcomes of stereotactic ablative radiotherapy for centrally located early-stage lung cancer.

Authors:  Cornelis J A Haasbeek; Frank J Lagerwaard; Ben J Slotman; Suresh Senan
Journal:  J Thorac Oncol       Date:  2011-12       Impact factor: 15.609

8.  Stereotactic body radiotherapy for central lung tumors.

Authors:  Bryan P Rowe; Daniel J Boffa; Lynn D Wilson; Anthony W Kim; Frank C Detterbeck; Roy H Decker
Journal:  J Thorac Oncol       Date:  2012-09       Impact factor: 15.609

Review 9.  Outcomes of stereotactic ablative radiotherapy for central lung tumours: a systematic review.

Authors:  Sashendra Senthi; Cornelis J A Haasbeek; Ben J Slotman; Suresh Senan
Journal:  Radiother Oncol       Date:  2013-02-22       Impact factor: 6.280

10.  Esophageal toxicity from high-dose, single-fraction paraspinal stereotactic radiosurgery.

Authors:  Brett W Cox; Andrew Jackson; Margie Hunt; Mark Bilsky; Yoshiya Yamada
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-05-07       Impact factor: 7.038

View more
  13 in total

Review 1.  Revisiting the dose constraints for head and neck OARs in the current era of IMRT.

Authors:  N Patrik Brodin; Wolfgang A Tomé
Journal:  Oral Oncol       Date:  2018-09-08       Impact factor: 5.337

Review 2.  Simple Factors Associated With Radiation-Induced Lung Toxicity After Stereotactic Body Radiation Therapy of the Thorax: A Pooled Analysis of 88 Studies.

Authors:  Jing Zhao; Ellen D Yorke; Ling Li; Brian D Kavanagh; X Allen Li; Shiva Das; Moyed Miften; Andreas Rimner; Jeffrey Campbell; Jinyu Xue; Andrew Jackson; Jimm Grimm; Michael T Milano; Feng-Ming Spring Kong
Journal:  Int J Radiat Oncol Biol Phys       Date:  2016-03-25       Impact factor: 7.038

3.  Optimizing the flattening filter free beam selection in RapidArc®-based stereotactic body radiotherapy for Stage I lung cancer.

Authors:  J-Y Lu; Z Lin; P-X Lin; B-T Huang
Journal:  Br J Radiol       Date:  2015-07-02       Impact factor: 3.039

4.  Systematic Review of Normal Tissue Complication Models Relevant to Standard Fractionation Radiation Therapy of the Head and Neck Region Published After the QUANTEC Reports.

Authors:  N Patrik Brodin; Rafi Kabarriti; Madhur K Garg; Chandan Guha; Wolfgang A Tomé
Journal:  Int J Radiat Oncol Biol Phys       Date:  2017-09-29       Impact factor: 7.038

Review 5.  Organs at Risk Considerations for Thoracic Stereotactic Body Radiation Therapy: What Is Safe for Lung Parenchyma?

Authors:  Feng-Ming Spring Kong; Vitali Moiseenko; Jing Zhao; Michael T Milano; Ling Li; Andreas Rimner; Shiva Das; X Allen Li; Moyed Miften; ZhongXing Liao; Mary Martel; Soren M Bentzen; Andrew Jackson; Jimm Grimm; Lawrence B Marks; Ellen Yorke
Journal:  Int J Radiat Oncol Biol Phys       Date:  2018-11-26       Impact factor: 8.013

6.  Clinical evaluation of stereotactic radiation therapy for recurrent or second primary mediastinal lymph node metastases originating from non-small cell lung cancer.

Authors:  Mao-Bin Meng; Huan-Huan Wang; Nicholas G Zaorsky; Xian-Zhi Zhao; Zhi-Qiang Wu; Bo Jiang; Yong-Chun Song; Hong-Qing Zhuang; Feng-Tong Li; Lu-Jun Zhao; Chang-Li Wang; Kai Li; Ping Wang; Zhi-Yong Yuan
Journal:  Oncotarget       Date:  2015-06-20

Review 7.  Complications from Stereotactic Body Radiotherapy for Lung Cancer.

Authors:  Kylie H Kang; Christian C Okoye; Ravi B Patel; Shankar Siva; Tithi Biswas; Rodney J Ellis; Min Yao; Mitchell Machtay; Simon S Lo
Journal:  Cancers (Basel)       Date:  2015-06-15       Impact factor: 6.639

Review 8.  Advances in dosimetry and biological predictors of radiation-induced esophagitis.

Authors:  Yang Yu; Hui Guan; Yuanli Dong; Ligang Xing; Xiaolin Li
Journal:  Onco Targets Ther       Date:  2016-01-28       Impact factor: 4.147

Review 9.  Radiobiological Optimization in Lung Stereotactic Body Radiation Therapy: Are We Ready to Apply Radiobiological Models?

Authors:  Marco D'Andrea; Silvia Strolin; Sara Ungania; Alessandra Cacciatore; Vicente Bruzzaniti; Raffaella Marconi; Marcello Benassi; Lidia Strigari
Journal:  Front Oncol       Date:  2018-01-08       Impact factor: 6.244

10.  Hypofractionated Volumetric-Modulated Arc Radiotherapy for Patients With Non-Small-Cell Lung Cancer Not Suitable for Surgery or Conventional Chemoradiotherapy or SBRT.

Authors:  Junyue Shen; Dan Yang; Mailin Chen; Leilei Jiang; Xin Dong; Dongming Li; Rong Yu; Huiming Yu; Anhui Shi
Journal:  Front Oncol       Date:  2021-06-16       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.